A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

A Phase 3 Randomized, Controlled Study to Assess the Efficacy and Safety of NVD003 Compared With Iliac Crest Bone Graft in Pediatric Participants Treated Surgically for Congenital Pseudarthrosis of the Tibia

The purpose of this study is to assess the efficacy and safety of NVD003 in pediatric participants with unilateral Congenital Pseudarthrosis of the Tibia (CPT) compared with iliac crest bone graft (ICBG) at 12 months post graft surgery.

Study Overview

• Status: Recruiting
• Conditions: Congenital Pseudarthrosis of Tibia
• Intervention / Treatment: Biological: NVD003; Procedure: Iliac Crest Bone Graft

Detailed Description

CPT is a rare disorder affecting the tibia and/or the ipsilateral fibula in children. The disease is usually diagnosed during the first year of life and is characterized by nonunion of a tibial diaphyseal fracture that either develops spontaneously or after a history of trivial trauma in a previously dysplastic segment of the bone. The treatment of CPT remains a challenge, often due to failure of ICBG to achieve and maintain bone union, resulting in multiple revision surgeries and occasionally amputation of the lower leg. NVD003 is a novel 3-dimensional osteogenic graft that is derived from autologous adipose stem cells combined with hydroxyapatite/beta-tricalcium phosphate particles. As an alternative to ICBG, NVD003 is intended to promote bone formation and support the bone healing process, even in severely disturbed pathophysiological conditions like CPT.

This is a prospective, randomized, controlled, multicenter, phase 3 clinical study in pediatric participants with CPT who have a non-healing Paley type 3 or 4 diaphyseal fracture and are candidates to undergo surgical treatment with internal fixation (intramedullary rod).

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Judy Ashworth, MD; Phone Number: 224-713-6154; Email: clinical@novadip.com
• Study Contact Backup: Name: Lola TOME; Phone Number: +447468479913; Email: regulatory@novadip.com

Study Locations

• Belgium
  • Brussels Capital
    • Brussels, Brussels Capital, Belgium, 1200
      • Recruiting
      • Cliniques Universitaires Saint-Luc ASBL (CUSCL)
      • Principal Investigator: Pierre-Louis Docquier, Pr.
• France
  • Picardie
    • Amiens, Picardie, France, 80000
      • Recruiting
      • CHU Amiens-Picardie
      • Principal Investigator: Céline Klein, Pr.
• Spain
  • Esplugues de Llobregat, Spain, 08950
    • Recruiting
    • Hospital Sant Joan de Déu
    • Contact: CÉSAR GALO GARCÍA FONTECHA, DR.
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Recruiting
      • Phoenix Children's Hospital, Inc.
      • Principal Investigator: Mohan Belthur, MD
  • California
    • Loma Linda, California, United States, 92354
      • Recruiting
      • Loma Linda University Health
      • Principal Investigator: Corey Fuller, MD
  • Maryland
    • Baltimore, Maryland, United States, 21117
      • Recruiting
      • LifeBridge Health - International Center for Limb Lengthening
      • Principal Investigator: Philip McClure, MD
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Recruiting
      • Mayo Clinic
      • Principal Investigator: Noelle A Larson, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participant's parent(s)/legal guardian(s) have provided written informed consent (and assent has been provided by the participant, depending on age) for the study.
2. Participant is of any sex, ≤17 years of age.
3. Participant has been diagnosed with CPT (with or without NF1).
4. Participant has a non-healing Paley type 3 or 4 diaphyseal fracture.4
5. Participant is a candidate for surgical treatment using an internal fixation approach (intramedullary rod) based on CPT fracture status and general health status.
6. Participant has serology and molecular test results at Visits 1 and 2 excluding the presence of human T-cell lymphoma virus, human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis.
7. Participant can provide an adequate ATC sample volume.
8. Participant weighs ≥5 kg/11 lb at Screening and on Day 1.
9. Participant is not pregnant or lactating.

10. If participant is of childbearing potential, is practicing highly effective methods of birth control from Screening to the end of the study:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Intravaginal
      • Transdermal

    • Progestogen-only hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Injectable
      • Implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Sexual abstinence, defined as refraining from heterosexual intercourse during study participation, is acceptable if this is the participant's usual lifestyle; periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and the lactational amenorrhea method are not acceptable methods of contraception Note: A participant is considered to be of childbearing potential if they are postmenarchal and premenopausal, unless surgically sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy).

    If participant is sexually active and has a partner who may become pregnant (i.e., neither surgically sterile nor postmenopausal), agrees to use highly effective contraception (e.g., sterilization, birth control pills, Depo Provera injections, or contraceptive implants) from Screening to the end of the study.

    Participant agrees to refrain from donating sperm or eggs from Screening to the end of the study.

11. Participant and parent(s)/legal guardian(s) are able to understand all study information provided and are willing to return to the study facility for all visits, including follow-up evaluations.

Exclusion Criteria:

1. Participant has bilateral CPT.
2. Participant has evidence of plexiform neurofibroma of any size or nodular fibroma ≥1.2 inches/3 cm on the ipsilateral leg.
3. Participant has a clinically significant infection at the fracture site or systemic infection.
4. Participant's CPT fracture involves the metaphysis (i.e., not limited to the diaphysis).
5. Participant has a CPT fracture, for which the surgeon intends to use an external fixation system (e.g., Ilizarov, Taylor spatial frame, rail, etc.) instead of, or in addition to, internal fixation.
6. Participant has an autoimmune disease, with the exception of well-controlled type 1 diabetes or autoimmune thyroid disorders.
7. Participant has an active (malignant) tumor.
8. Participant has documented metabolic bone disease or any disorder, such as, but not limited, to osteogenesis imperfecta and osteomalacia, that could interfere with bone healing and bone metabolism.

9. Participant has any chronic, ongoing, or planned use of medications that might affect bone metabolism or bone quality such as bisphosphonates, steroids, methotrexate, vitamin K antagonists, immunosuppressant therapy, or immunotherapy during the study.

   Note that perioperative treatment with a bisphosphonate is allowed in Cohort A participants randomized to ICBG if its use is deemed SOC by the treating surgeon.

10. Participant has any history of allergic reaction or any anticipated hypersensitivity to any anesthetic agent or any potential hypersensitivity to any of the components of the NVD003 graft (including the CMRL1066 formulation medium) or hypersensitivity related to other factors in the surgical process for the ICBG graft, such as anesthesia, medications, suture materials or fixation devices.
11. Participant has received any investigational product (including a device) within 60 days before enrollment in the study.
12. Participant would be concurrently enrolled in another clinical study while participating in this study.
13. Participant has any clinically significant hematologic, renal, hepatic, and coagulation laboratory abnormalities (i.e., complete blood count, prothrombin time/international normalized ratio, Chem-7, liver function tests, etc.).
14. Participant or participant's parent(s)/legal guardian(s) have an unstable condition (e.g., psychiatric disorder, a recent history of substance abuse) or is otherwise thought to be unreliable or incapable of complying with the requirements of the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental Arm; surgical grafting procedure: internal fixation with cross-union using NVD003	Biological: NVD003; Bone correction and grafting surgery
Active Comparator: Standard of Care Arm; Either a single-stage grafting surgery with internal fixation and cross-union or the 2-stage "induced membrane" grafting surgery approach, depending on the surgeon's own standard of Care.	Procedure: Iliac Crest Bone Graft; Either a single-stage Grafting Surgery with internal fixation and cross-union or the 2-stage "induced membrane" Grafting Surgery approach, depending on the surgeon's own standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the efficacy of NVD003 for the surgical treatment of CPT in pediatric participants	Overall healing at 12 months, defined as a binary (yes/no) outcome derived from the following 3 outcomes: Radiographic healing, defined as a score ≥13 on the modified Radiological Union Scale for Tibia (mRUST) scale (range 1 to 16) assessed by independent central readers (ICRs); Clinical healing measured by the absence of pain with weight-bearing, based on clinician's assessment; No use of secondary interventions to promote or accelerate bone healing All 3 criteria must be met for a "yes" on overall healing for this endpoint to be achieved.	At 12 months post GS

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy: To assess the efficacy of NVD003 with respect to individual components of overall healing - radiographic healing	Radiographic healing, defined as a score ≥13 on the modified Radiological Union Scale for Tibia (mRUST) scale (range 1 to 16) assessed by independent central readers (ICRs)	12 months after grafting surgery
Efficacy: To assess the efficacy of NVD003 with respect to individual components of overall healing - clinical healing	Clinical healing measured by the absence of pain with weight-bearing, based on clinician's assessment	12 months after grafting surgery
Efficacy: To assess the efficacy of NVD003 with respect to individual components of overall healing - No use of secondary intervention	No use of secondary interventions to promote or accelerate bone healing	12 months after grafting surgery
Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - Adverse events	Number and severity of adverse events (AEs) related to NVD003	12 months after grafting surgery
Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - Serious adverse events	Number of serious adverse events (SAEs) related to NVD003	12 months after grafting surgery
Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - Units of blood transfused perioperatively	Units of blood transfused perioperatively (in Liters or milliliters)	from start of surgical procedure (Day 1) until hospital discharge
Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - Duration of Grafting Surgery	Duration of Grafting Surgery (in hours)	Grafting Surgery (Day 1)
Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - duration of hospitalization	Duration of hospitalization after GS (in days)	from grafting surgery (Day 1) until hospital discharge
Safety: To assess the safety of NVD003 for the surgical treatment of CPT in pediatric participants - Recurrent fracture	Recurrent fracture within 12 months after GS	12 months after grafting surgery
To further evaluate the efficacy of NVD003 for the surgical treatment of CPT in pediatric participants based on other measures of bone healing - Radiological	• Radiological bone union status at 3, 6, and 12 months after Grafting Surgery, assessed centrally by independent central readers (ICRs) using the total extended Lane and Sandhu scoring (eLSS) method (maximum of 12 points)	Post grafting surgery (Day 1), and at months 3, 6 and 12
To further evaluate the efficacy of NVD003 for the surgical treatment of CPT in pediatric participants based on other measures of bone healing - functional walking	Functional walking outcome, assessed using the timed 10-meter walking test (when appropriate) post Grafting Surgery at 3, 6, and 12 months (in second)	Post grafting surgery (Day 1), and at months 3, 6 and 12
To evaluate the effects of NVD003 on quality of life (QoL)	Mean change from Baseline to 6 and 12 months after GS in QoL: Pediatric Outcomes Data Collection Instrument (PODCI) parent report for children 2 years of age and above. ("0" represents a poor outcome/worse health while "100" is the best possible outcome/best health.)	Baseline and months 6 and 12 post grafting surgery

Collaborators and Investigators

• Sponsor: Novadip Biosciences

Study record dates

Study Major Dates

• Study Start (Actual): September 2, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): July 1, 2027

Study Registration Dates

• First Submitted: July 23, 2025
• First Submitted That Met QC Criteria: August 1, 2025
• First Posted (Actual): August 8, 2025

Study Record Updates

• Last Update Posted (Actual): April 1, 2026
• Last Update Submitted That Met QC Criteria: March 31, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: pediatric; bone graft; autologous; cellular therapy; congenital; non-union; pseudarthrosis; tissue engineered therapy
• Additional Relevant MeSH Terms: Wounds and Injuries; Fractures, Bone; Fractures, Ununited; Pseudarthrosis
• Other Study ID Numbers: NVD003-CLN03; 2025-520998-39-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No